Melinda L Telli

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Novel treatment approaches for triple-negative breast cancer
    Melinda L Telli
    Department of Medicine, Stanford University School of Medicine, CA 94305 5820, USA
    Clin Breast Cancer 10:E16-22. 2010
  2. doi request reprint Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
    Melinda L Telli
    Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Breast Cancer Res Treat 127:471-8. 2011
  3. ncbi request reprint Trastuzumab-related cardiac dysfunction
    Melinda L Telli
    Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA 94305 5826, USA
    J Natl Compr Canc Netw 9:243-9. 2011
  4. pmc Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Geoffrey J Yoon
    Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA
    J Am Coll Cardiol 56:1644-50. 2010
  5. doi request reprint First-line chemotherapy for metastatic breast cancer
    Melinda L Telli
    Department of Medicine, Division of Medical Oncology, Stanford University, CA, USA
    Clin Breast Cancer 9:S66-72. 2009
  6. ncbi request reprint Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome
    Eve Henry
    Department of Medicine, Stanford University, Stanford, California, USA
    J Natl Compr Canc Netw 10:939-42. 2012
  7. pmc Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines
    Ashley A Powell
    Department of Surgery, Stanford University School of Medicine, Stanford, California, USA
    PLoS ONE 7:e33788. 2012
  8. doi request reprint Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
    Ronald M Witteles
    Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Falk CVRC, Stanford, CA 94305, USA
    Heart Fail Clin 7:333-44. 2011
  9. ncbi request reprint PARP inhibitors in breast cancer
    Melinda L Telli
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5151, USA
    Clin Adv Hematol Oncol 8:629-35. 2010
  10. pmc Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer
    Daniel I Golden
    Department of Radiology, Stanford University Medical Center, Stanford, California, USA
    J Am Med Inform Assoc 20:1059-66. 2013

Detail Information

Publications13

  1. doi request reprint Novel treatment approaches for triple-negative breast cancer
    Melinda L Telli
    Department of Medicine, Stanford University School of Medicine, CA 94305 5820, USA
    Clin Breast Cancer 10:E16-22. 2010
    ..Ongoing studies, including those investigating the role of antiangiogenic therapies, are also reviewed...
  2. doi request reprint Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
    Melinda L Telli
    Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Breast Cancer Res Treat 127:471-8. 2011
    ..Given the poor prognosis and high treatment costs of HER2-positive breast cancer, our results have implications for healthcare resource utilization, cancer biology, and clinical care...
  3. ncbi request reprint Trastuzumab-related cardiac dysfunction
    Melinda L Telli
    Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA 94305 5826, USA
    J Natl Compr Canc Netw 9:243-9. 2011
    ....
  4. pmc Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Geoffrey J Yoon
    Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA
    J Am Coll Cardiol 56:1644-50. 2010
    ....
  5. doi request reprint First-line chemotherapy for metastatic breast cancer
    Melinda L Telli
    Department of Medicine, Division of Medical Oncology, Stanford University, CA, USA
    Clin Breast Cancer 9:S66-72. 2009
    ....
  6. ncbi request reprint Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome
    Eve Henry
    Department of Medicine, Stanford University, Stanford, California, USA
    J Natl Compr Canc Netw 10:939-42. 2012
    ....
  7. pmc Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines
    Ashley A Powell
    Department of Surgery, Stanford University School of Medicine, Stanford, California, USA
    PLoS ONE 7:e33788. 2012
    ..Here we demonstrate feasibility of performing high dimensional single CTC profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast cancer cell lines widely used for drug discovery...
  8. doi request reprint Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
    Ronald M Witteles
    Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Falk CVRC, Stanford, CA 94305, USA
    Heart Fail Clin 7:333-44. 2011
    ....
  9. ncbi request reprint PARP inhibitors in breast cancer
    Melinda L Telli
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5151, USA
    Clin Adv Hematol Oncol 8:629-35. 2010
    ..We also provide commentary on a series of outstanding questions in the field, the answers to which will be critical for the successful development of PARP inhibitor-based strategies in early- and late-stage breast cancer...
  10. pmc Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer
    Daniel I Golden
    Department of Radiology, Stanford University Medical Center, Stanford, California, USA
    J Am Med Inform Assoc 20:1059-66. 2013
    ..To predict the response of breast cancer patients to neoadjuvant chemotherapy (NAC) using features derived from dynamic contrast-enhanced (DCE) MRI...
  11. doi request reprint Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls
    Maria M Gramatges
    Department of Pediatrics, Stanford, CA, USA
    Cancer Epidemiol Biomarkers Prev 19:605-13. 2010
    ..0001). Our analysis supports previous findings of longer RTL in breast cancer cases compared with controls, and is the first to observe longer RTL in women without breast cancer identified as high risk based on family history...
  12. ncbi request reprint Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility
    Melinda L Telli
    Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA, USA
    J Clin Oncol 25:3525-33. 2007
    ..To assess the spectrum and reversibility of the cardiotoxicity observed in the adjuvant trastuzumab trials...
  13. ncbi request reprint Phyllodes tumors of the breast: natural history, diagnosis, and treatment
    Melinda L Telli
    Department of Medicine, Stanford University, Stanford, CA, USA
    J Natl Compr Canc Netw 5:324-30. 2007
    ..Adjuvant systemic therapy is of no proven value. Patients with locally recurrent disease should undergo wide excision of the recurrence with or without subsequent radiotherapy...